Safety Information and Study Correspondence Distribution

Timely dissemination of critical safety information and ongoing study correspondence is imperative. Throughout the life of your clinical trial, BMA will reproduce, distribute, and track all safety and study correspondence. This can be done via fax, email, hard copy, or web-based posting.